Navigation Links
Kewaunee Scientific Reports Improved Results for Third Quarter
Date:2/26/2013

493,000 in the same period last year. Net earnings for the nine months ended January 31, 2013 were $1,827,000, or $0.71 per diluted share, as compared to a net loss of $225,000, or $0.09 per diluted share, in the comparable period last year.

The Company's balance sheet continues to be strong. Cash on hand was $4.9 million at the end of the quarter, as compared to $4.6 million at January 31, 2012.  Working capital was $24.3 million, as compared to $21.5 million at the end of the same period last year. Short-term borrowings under the Company's $15 million bank line of credit were $2.7 million, as compared to $6.4 million at January 31, 2012. Total bank borrowings and capital lease obligations were $6.2 million, as compared to $10.2 million at the end of the third quarter last year, and the debt-to-equity ratio was .20-to-1, as compared to .34-to-1.

"We continued to make excellent progress during the quarter," said William A. Shumaker, Kewaunee's Chief Executive Officer. "I am pleased with sales and earnings, particularly since the third quarter is historically our slowest due to normal construction cycles and the large number of holidays. We continue to see positive results from our strengthened domestic dealer network and our broadened international dealer network. When combined with our lower manufacturing costs, this is providing us with more opportunities to close orders in both of these geographic markets.

"Looking forward, we expect to have a strong finish to our year. Incoming orders and customer delivery requirements for our metal furniture, fume hoods, and epoxy resin products have provided us a strong backlog of orders scheduled to ship in the fourth quarter. This increased demand and our lower costs are expected to more than offset the continuing lower demand for publicly-funded wood educational projects. It should be mentioned that results for the fourth quarter of last year were unusually strong, as results were favo
'/>"/>

SOURCE Kewaunee Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
2. Kewaunee Scientific Corporation Declares Quarterly Dividend
3. Kewaunee Scientific Reports Record Sales for Second Quarter
4. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
5. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
6. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
7. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
8. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
9. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
10. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
11. Generex Augments Antigen Express Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015  Mirati Therapeutics, ... focusing on genetic and epigenetic drivers of cancer, will be ... August 11, 2015 at 1:55 p.m. ET (10:55 a.m. PT) ... Baum , M.D., Ph.D., president and CEO of Mirati, will ... of the presentation will be accessible on the "Investors" page ...
(Date:8/3/2015)... 2015   The Intellectual Property and Science ... provider of intelligent information for businesses and professionals ... Pharmaceutical R&D Factbook , the biopharmaceutical industry,s leading ... declines in R&D, the analysis identifies a surge ... and forecasts sales to reach $1.3 trillion by ...
Breaking Medicine Technology:Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3Pharma Sales to Grow Beyond $1 Trillion 2
... June 21, 2010 ReportsandReports announces it Will,Carry Cardiovascular Devices Market ... , , ... http://www.reportsandreports.com/market-reports/netherlands-cardiovascular-de ,vices-market-outlook-to-2016/) , , , ... (Due to the length of these URLs, it may be necessary to copy ...
... AHMEDABAD, India , June 21, 2010 ... healthcare companies has,received Phase I clinical trial permission from the DCGI for ... Centre using a,unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule. ... ...
Cached Medicine Technology:Cardiovascular Devices Market Outlook June Update by ReportsandReports 2Cardiovascular Devices Market Outlook June Update by ReportsandReports 3Cardiovascular Devices Market Outlook June Update by ReportsandReports 4Cardiovascular Devices Market Outlook June Update by ReportsandReports 5Cardiovascular Devices Market Outlook June Update by ReportsandReports 6Cardiovascular Devices Market Outlook June Update by ReportsandReports 7Cardiovascular Devices Market Outlook June Update by ReportsandReports 8Cardiovascular Devices Market Outlook June Update by ReportsandReports 9Cardiovascular Devices Market Outlook June Update by ReportsandReports 10Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 2Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 3
(Date:8/4/2015)... ... 04, 2015 , ... Increasingly, patients are researching online to ... In an effort to share more and better information with these savvy and ... share patient satisfaction ratings and comments about its doctors and advanced practice providers. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mesothelioma researchers ... come back: Retreatment may be a viable option. Surviving Mesothelioma has just posted ... , According to surgeons at the University of New South Wales, peritoneal ...
(Date:8/4/2015)... ... August 04, 2015 , ... Sin ... unique artistic expressions from a diverse group of exceptionally talented female artists. ... & Art Festival on September 25-27, 2015 in Downtown Las Vegas. Curated by ...
(Date:8/4/2015)... New York, NY (PRWEB) , ... August 04, ... ... FHA multifamily mortgage lender specializing in healthcare finance, announced the closing of a ... operates a two campus health system located in Smithfield and Clayton, North Carolina. ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... The ... designed to treat Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were ... Academy of Ophthalmology. According to the results of the trial, the implant, more commonly ...
Breaking Medicine News(10 mins):Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2
... , NEW YORK, Nov. 18 WAT,s-THE-WORD?! is the first ... products, discoveries on the web and real-life experiences from a ... boys who helped their parents conceive the brand WAT-AAH! ... mom a "cooler" and better name for water, thus WAT-AAH!. ...
... 18 Banfield, The Pet Hospital® today announced ... its medical specialist/nutritionist. With nearly 20 years experience in veterinary ... platform that will position Banfield as a leader in veterinary ... as part of the Medical Quality Advancement team at Banfield,s ...
... , WASHINGTON, Nov. 18 The Union Labor ... subsidiary of ULLICO Inc., a privately held financial and ... provide pharmacy benefit management services to labor group clients. ... union employers and their members with a comprehensive pharmacy ...
... Institutet have discovered that patients with recent-onset schizophrenia have ... findings offer hope of being able to treat schizophrenia ... The causes of schizophrenia are largely unknown, and this ... that infections caught early on in life might increase ...
... have shown that lipid peroxidation stimulates collagen production ... plays an important role in the development of ... carbon tetrachloride, cholestasis and alcohol induced liver fibrosis ... effect of green tea in dimethylnitrosamine (DMN)-induced models ...
... stall carotid artery disease , WEDNESDAY, Nov. 18 (HealthDay ... additional benefit to seniors with coronary artery disease who ... , The 18-month study of 145 Baltimore-area men and ... arterial wall thickness reductions between those who took 1,500 ...
Cached Medicine News:Health News:WAT-AAH!, The First Functional Bottled Water For Kids, Announces The Release of WAT's-THE-WORD?! 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 3Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 3Health News:Immune system activated in schizophrenia 2Health News:Niacin Adds No Benefit for Statin Patients: Study 2
... The Ray TFC Unite Device is the ... The Ray TFC Unite device features the same ... contact offered by fenestrations is paramount in the ... the Ray TFC Unite system promotes load sharing ...
... The INTER FIX and ... Devices are designed to maximize ... of the implant. Both the ... RP Threaded Fusion devices combine ...
... Confirmatory (Western Blot): The Genetic Systems HIV-1 ... for the detection of antibodies to HIV-1. The ... of HIV-1 grown in the CEM cell line. ... devoid of HLA Class ll antigens, helps reduce ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
Medicine Products: